Research Article

Prestroke Metformin Use on the 1-Year Prognosis of Intracerebral Hemorrhage Patients with Type 2 Diabetes

Wen-Jun Tu,1,2 Qingjia Zeng,3 Kai Wang,4 Yu Wang,5 Bao-Liang Sun,6 Xianwei Zeng,7,8,9 and Qiang Liu1

1Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
3School of Healthcare Science, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M156GX, UK
4Department of Neurology, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
5Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
6Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
7Rehabilitation Hospital of the National Research Center for Rehabilitation Technical Aids, Beijing, China
8Department of Neurosurgery, Shandong University Qilu Hospital, Jinan, China
9People’s Hospital of Ningjin County, Dezhou, China

Correspondence should be addressed to Xianwei Zeng; wfzwxin@126.com and Qiang Liu; liuqiang_cams@163.com

Received 6 April 2021; Revised 29 July 2021; Accepted 16 August 2021; Published 15 September 2021

Academic Editor: Antonio Desmond McCarthy

Copyright © 2021 Wen-Jun Tu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although recent studies have focused on the use of metformin in treating ischemic stroke, there is little literature to support whether it can treat intracerebral hemorrhage (ICH). Therefore, this study is aimed at evaluating the possible effects of prestroke metformin (MET) on ICH patients with type 2 diabetes.

Methods. From January 2010 to December 2019, all first-ever ICH patients with type 2 diabetes from our hospitals were included. All discharged patients would receive a one-time follow-up at 1 year after admission. Death, disability, and recurrence events were recorded.

Results. We included 730 patients for analysis (the median age: 65 [IQR, 56-72] years and 57.7% was men). Of those patients, 281 (38.5%) had received MET before ICH (MET+), whereas 449 (61.5%) had not (MET−). MET (+) patients had a lower median baseline hematoma volume than did MET (−) patients (9.6 ml [IQR, 5.3-22.4 ml] vs. 14.7 ml [IQR, 7.9-28.6 ml]; \( P < 0.001 \)). The inhospital mortality events were not significantly reduced in the MET (+) group compared with the MET (−) group (6.4% vs 8.9%, respectively; absolute difference, −2.5% [95% CI, −3.9% to −0.7%]; OR, 0.70 [95% CI, 0.39 to 1.27]; \( P = 0.22 \)). The 1-year mortality events were not significantly reduced in the MET (+) group compared with the MET (−) group (4.6% vs 8.9%, respectively; absolute difference, −4.3% [95% CI, −5.1% to −1.8%]; OR, 0.67 [95% CI, 0.47 to 1.04]; \( P = 0.16 \)). The 1-year disability events were not significantly reduced in the MET (+) group compared with the MET (−) group (32.4% vs 34.1%, respectively; absolute difference, −1.7% [95% CI, −2.8% to −0.6%]; OR, 0.79 [95% CI, 0.52 to 1.21]; \( P = 0.18 \)). Finally, the recurrence rates in those two groups were not significantly different (MET [+]) vs. MET [−]: 6.4% vs. 5.9%; absolute difference, 0.5% [95% CI, 0.2% to 1.3%]; OR, 1.08 [95% CI, 0.51 to 2.28]; \( P = 0.84 \)).

Conclusions. Pre-ICH metformin use was not associated with inhospital mortality and 1-year prognosis in diabetic ICH patients.

1. Background

Metformin is the first-line drug for the treatment of type 2 diabetes mellitus [1]. It could prevent against diabetes complications [2]. Recent studies have established that metformin possesses antioxidant effects [3]. Metformin therapy could reduce oxidative stress levels in patients with type 2 diabetes [4, 5]. Metformin treatment in type 2 diabetic patients could activate oxidative stress together with the antioxidant system [6].

In addition to treating diabetes, metformin also plays an essential role in the treatment of other diseases, such as
anticancer [7], antiaging [8, 9], treatment of gestational hypertension [10] and hypertension [11], and weight loss [12]. In addition, metformin use could reduce the risk of hypertension [13] and stroke [14]. The neuroprotection role of metformin in cerebral ischemia had been suggested [3, 15]. Previous studies had shown that metformin treatment had a better functional outcome in patients with diabetes and ischemic stroke [16, 17]. However, metformin therapy might also have no effect or even worsen recovery following cerebral I/R injury [18]. Another study showed that metformin use was associated with a high risk of stroke in hemodialysis patients with type 2 diabetes [19].

Furthermore, the associations between metformin treatment and prognosis in intracerebral hemorrhage (ICH) patients with diabetes have not been discussed. ICH was associated with higher mortality and poorer neurologic outcomes than ischemic stroke [20]. Qi et al. [21] suggested that metformin was a potential clinical treatment for ICH patients. It is a meaningful topic to study the use of metformin and the prognosis of ICH patients with diabetes. Therefore, this study is aimed at evaluating the possible effects of metformin on ICH patients with type 2 diabetes.

2. Patients and Methods

From January 2010 to December 2019, all first-ever ICH [ICD61] patients from our hospitals were screened. Patients were eligible for inclusion if they were admitted to the hospitals with a stroke defined according to the World Health Organization criteria [22]. Patients with advanced tumors, infratentorial or traumatic hemorrhage, age < 18 years, pregnancy, the transformation of cerebral infarction, and hospital stay less than 24 hours were excluded. Furthermore, ICH patients with type 2 diabetes (T2DM) were included in this study. T2DM included self-reported diabetes and newly diagnosed diabetes during hospitalization according to the WHO diagnostic criteria (fasting plasma glucose ≥ 7.0 mmol/l or oral glucose tolerance test: two – hour plasma glucose ≥ 11.1 mmol/l) [23]. The Human Research Ethics Committee of the Shandong University Qilu Hospital checked and approved the study protocol. All enrolled patients need to sign an informed consent form before enrolment.

At admission, demographic information (age, sex, race/ethnicity, body mass index [BMI], province), comorbidities and risk factors (smoking, drinking, duration of diabetes, hypertension, dyslipidemia, atrial fibrillation, coronary heart disease, coagulopathy, hyperhomocysteinemia, a family history of stroke, and transient ischaemic attack [TIA]), pre-stroke (antihypertensive, antiplatelet agents, statins, insulin therapy, and metformin [MET] treatment), and acute treatment were recorded. Also, the following information also had been collected: marital status, education status, the time from symptom onset to hospital arrival, transported to hospital by emergency medical service [EMS], length of stay, hospitalization costs/patient, and payment style (public medical care and self-funded medical care). Finally, discharge information, including death, discharge according to medical advice, and discharge according to medical advice, were collected.

ICH severity on admission was assessed by the Glasgow Coma Scale (GCS). According to the study protocol, MRI and/or CT was used to verify the ICH diagnosed within 24h of hospital admission. Intraventricular hemorrhage expansion, if present, was also documented. ICH volumes were quantified using the \((a \times b \times c)/2\) method [24]. Systolic blood pressure and diastolic blood pressure were tested at admission. Fasting serum blood samples were collected, and serum levels of glucose, homocysteine (HCY), C-reactive protein (CRP), and blood lipids were tested in the laboratory.

2.1. Follow-Up. All discharged patients would receive a one-time follow-up at 1 year after admission. Outcome assessment was performed by study staff members blinded to all clinical and laboratory variables with a structured follow-up telephone interview with the patient or the closest relative. Death (all-cause), disability, and recurrence events were recorded. Functional outcomes were assessed in the follow-up by a Modified Rankin Scale (mRS) score (range from 0 to 6) [25]. Disability events were defined as an mRS of 3 to 5 points. Stroke recurrence events were defined as suddenly deteriorated neurological function evaluated as a decreased NIHSS score of 4 or more, or a new focal neurological deficit of vascular origin that lasted for >24 hours [26].

2.2. Statistical Analysis. Continuous and categorical variables were presented as medians (interquartile ranges [IQR]) and frequencies (%), respectively. Mann–Whitney test (Continuous variables) and chi-square test (categorical variables) were used to compare groups.

Crude rate estimate and 95% confidence interval (CI) for mortality, disability, and stroke recurrence events were assessed. The included patients were divided into two groups: MET (+) group and MET (-) group, according to prestroke MET use (yes or no). With all comparative outcomes between those two groups, cumulative rates and absolute differences with 95% CIs were presented. Regression models were performed to compare the outcomes between MET (+) and MET (-) groups, and odds ratios (OR) with 95% CIs were presented. Multivariate regression analysis adjusted for patient characteristics, including age, sex, family history of ICH, hypertension, diabetes duration, hyperlipidemia, atrial fibrillation, smoking, drinking, pre-stroke therapy (including oral anticoagulants, antiplatelet agents, antihypertensive treatment, and statins), ICH volumes, and NIHSS score at admission. Finally, to study MET’s ability for mortality prediction, Kaplan–Meier survival curves stratified patients by MET use or not were calculated. All statistical analyses were conducted with SAS version 9.4 and Stata version 14.1. \(P < 0.05\) was the threshold for statistical significance.

3. Results

3.1. Patients. From 6907, screened patients with first-ever ICH, 6114 patients were included, and 730 patients with
T2DM (11.9%) were selected for analysis. Of those patients, 281 (38.5%) had received MET before ICH (MET+), whereas 449 (61.5%) had not (MET−) (Figure 1).

3.2. Descriptive Characteristics of Selected Patients. The median age of 730 ICH patients with T2DM was 65 (IQR, 56-72) years, and 57.7% were men. Only 2.1% of patients are younger than 40. The median duration of diabetes was 12 years (IQR, 7-18). Median systolic blood pressure was 159 mm Hg (IQR, 140-175 mm Hg), and the median diastolic blood pressure was 90 (IQR, 80-130 mm Hg). A total of 651 patients (89.2%) had a history of hypertension, 126 (17.3%) had hypercholesterolemia, 31 (4.2%) had a history of stroke, 144 (19.7%) were smokers, and 132 (18.1%) were drinkers. A total of 118 (16.2%) patients were with time from symptom onset to hospital arrival within two h, and 132 (18.1%) patients were transported to hospital by EMS. On admission, the median GCS score was 12 (IQR, 8–16) points, and the median ICH volume was 11.8 ml (IQR, 6.5-26.7). The median length of stay was 13 days (IQR, 8-21), and the median hospitalization costs 17253 CNY (IQR, 9802-39943). Demographic characteristics and clinical information of those included ICH patients were presented in Table 1.

3.3. Main Results. MET (+) patients had a lower median baseline hematoma volume than did MET (−) patients (9.6 ml [IQR, 5.3-22.4 ml] vs. 14.7 ml [IQR, 7.9-28.6 ml]; P < 0.001) Figure 2. MET was not associated with baseline GCS score (P=0.15). In addition, MET use was not associated with age (P=0.35), sex (P=0.78), hospitalization stay (P=0.53), and cost (P=0.87).

At discharge, fifty-eight patients died, and the inhospital mortality rate was thus 7.9% (6.0-9.9%). The inhospital mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (6.4% vs 8.9%, respectively; absolute difference, −2.5% [95% CI, −3.9% to −0.7%]; OR, 0.70 [95% CI, 0.39 to 1.27]; P = 0.22). In addition, the discharge against medical advice events was also not significantly reduced in the MET (+) group compared with the MET (-) group (10.7% vs 11.8%, respectively; absolute difference, −1.1% [95% CI, −2.3% to −0.3%]; OR, 0.89 [95% CI, 0.56 to 1.44]; P = 0.64), Table 2.

In the 1-year follow-up, 73 patients lost follow-up, and 599 (90.1%) finished the follow-up. As shown in Table 2, the 1-year mortality rate was 18.0% (95% CI: 15.0-21.1%), and the disability and recurrence rates among survivors were 31.8% (95% CI: 27.7%-35.9%) and 6.1% (95% CI: 4.0%-8.2%), respectively, Table 2.
The 1-year mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (14.1% vs 17.4%, respectively; absolute difference, -3.3% [95% CI, -5.1% to -1.8%]; OR, 0.73 [95% CI, 0.47 to 1.14]; P = 0.16). The time to death was analyzed by Kaplan–Meier survival curves based on MET use. Patients in the MET (+) group did not have a minimal risk for death, in contrast with patients in the MET (-) group (P = 0.016) (Figure 3). The mRS score among survivors in the follow-up was shown in Figure 4. The 1-year disability events were not significantly reduced in the MET (+) group compared with the MET (-) group (28.4% vs 34.1%, respectively; absolute difference, -5.7% [95% CI, -8.2% to -3.3%]; OR, 0.77 [95% CI, 0.52 to 1.31]; P = 0.18). Finally, the recurrence rates in those two groups were not significantly different (MET [+] vs. MET [-]): 6.4% vs. 5.9%; absolute difference, 0.5% [95% CI, 0.2% to 1.3%]; OR, 1.08 [95% CI, 0.51 to 2.28]; P = 0.84).

The 1-year mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (14.1% vs 17.4%, respectively; absolute difference, -3.3% [95% CI, -5.1% to -1.8%]; OR, 0.73 [95% CI, 0.47 to 1.14]; P = 0.16). The time to death was analyzed by Kaplan–Meier survival curves based on MET use. Patients in the MET (+) group did not have a minimal risk for death, in contrast with patients in the MET (-) group (P = 0.016) (Figure 3). The mRS score among survivors in the follow-up was shown in Figure 4. The 1-year disability events were not significantly reduced in the MET (+) group compared with the MET (-) group (28.4% vs 34.1%, respectively; absolute difference, -5.7% [95% CI, -8.2% to -3.3%]; OR, 0.77 [95% CI, 0.52 to 1.31]; P = 0.18). Finally, the recurrence rates in those two groups were not significantly different (MET [+] vs. MET [-]): 6.4% vs. 5.9%; absolute difference, 0.5% [95% CI, 0.2% to 1.3%]; OR, 1.08 [95% CI, 0.51 to 2.28]; P = 0.84).

In univariate logistic regression analysis, hematoma volume had a strong association with 1-year mortality and disability events, with the unadjusted ORs that were 1.11 (95% CI, 1.03–1.21) and 1.08 (95% CI, 1.01–1.17), respectively. After adjusting for MET use and other significant predictors, hematoma volume remained an independent outcome predictor for mortality and disability events, with the adjusted ORs that were 1.07 (95% CI, 1.01–1.15) and 1.05 (95% CI, 1.00–1.11), respectively. Furthermore, in

Table 1: Demographic characteristics and clinical information of those included ICH patients.

| ICH     | N      | Sex-male, n (%) | Age, median (IQR), years | Sex-male, n (%) | Age, median (IQR), years |
|---------|--------|-----------------|--------------------------|-----------------|--------------------------|
| N       | 730    | 421 (57.7)      | 65 (56-72)               | 421 (57.7)      | 65 (56-72)               |
| < 40    | 15     | 244 (33.4)      | 471 (64.5)               | 244 (33.4)      | 471 (64.5)               |
| > 60    | 471    | 708 (97.0)      | 699 (95.8)               | 708 (97.0)      | 699 (95.8)               |
| Race-Chinese Han | 132 | 118 (16.2)  | 132 (18.1)               | 132 (18.1)      | 118 (16.2)               |
| Marital status-married | 44 | 44 (6.0)     | 44 (6.0)                 | 44 (6.0)        | 44 (6.0)                 |
| Patients with time from symptom onset to hospital arrival within 2 h | 118 | 118 (16.2)  | 118 (16.2)               | 118 (16.2)      | 118 (16.2)               |
| BMI, kg/m² | 23.66 (22.01-25.53) | 23.66 (22.01-25.53) | 23.66 (22.01-25.53) | 23.66 (22.01-25.53) | 23.66 (22.01-25.53) |
| Systolic pressure, mmHg | 159 | 159 (140-175)  | 159 (140-175)             | 159 (140-175)   | 159 (140-175)             |
| Diastolic pressure, mmHg | 90  | 90 (80-103)    | 90 (80-103)               | 90 (80-103)     | 90 (80-103)               |
| Duration of diabetes, median (IQR), years | 12  | 12 (7-18)     | 12 (7-18)                | 12 (7-18)       | 12 (7-18)                |
| Comorbidities |          |                  |                          |                  |                          |
| Hypertension | 651 | 89.2           | 126 (17.3)               | 126 (17.3)      | 651 (89.2)               |
| Dyslipidemia | 29   | 29 (4.0)       | 31 (4.2)                 | 31 (4.2)        | 29 (4.0)                 |
| Atrial fibrillation | 18  | 18 (2.5)       | 18 (2.5)                 | 18 (2.5)        | 18 (2.5)                 |
| Coronary heart disease | 41  | 41 (5.6)       | 41 (5.6)                 | 41 (5.6)        | 41 (5.6)                 |
| Coagulopathy | 31   | 31 (4.2)       | 31 (4.2)                 | 31 (4.2)        | 31 (4.2)                 |
| Hyperhomocysteinemia | 11  | 11 (1.5)       | 11 (1.5)                 | 11 (1.5)        | 11 (1.5)                 |
| Duration of diabetes, median (IQR), years | 12  | 12 (7-18)     | 12 (7-18)                | 12 (7-18)       | 12 (7-18)                |

Table 1: Continued.

| ICH     | N      | Length of stay, days | Hospitalization costs/patient, CNY | Payment style-no medical insurance |
|---------|--------|----------------------|-----------------------------------|------------------------------------|
| N       | 730    | 13 (8-21)            | 17253 (9802-39943)                | 61 (8.4)                           |

Abbreviation: ICH: intracerebral hemorrhage; GCS: Glasgow Coma Scale; mRS: Modified Rankin Scale; EMS: emergency medical service; CNY: China Yuan; IQR: interquartile ranges; TIA: transient ischemic attack.*The continuous variables are presented as median with interquartile ranges (IQRs) and categorical variables as frequency and percentage (95% CI).
4. Discussion

In this study, we assess the effect of prestroke metformin use on 1-year prognosis in ICH patients with T2DM. The data showed that pre-ICH metformin use was not associated with inhospital mortality and 1-year prognosis in diabetic ICH patients. Improving the prognosis of diabetic ICH patients by taking metformin requires further verification.

Different from our conclusion, a single-center Helsinki ICH study, including 374 ICH patients with diabetes, showed that pre-ICH metformin use was associated with improved outcomes in diabetic ICH patients [27]. It should be noted that the Helsinki ICH study was a retrospective analysis of consecutive ICH patients. In addition, the differences in acute treatment and ethnicity of the enrolled patients might have caused the inconsistency of the study results. Another study suggested that patients with ischemic stroke and diabetes on treatment with MET receiving intra-venous thrombolysis had a better functional outcome at three months [17]. In addition, the use of metformin could reduce cardiovascular events in patients with T2DM [28]. Metformin treatment was associated with reduced cardiovascular risk (mortality and incidence) [29] and all-cause mortality [30]. A meta-analysis showed that metformin reduced cardiovascular mortality, all-cause mortality, and cardiovascular events in patients with coronary artery diseases [31]. Furthermore, long-term adherence to metformin was associated with decreased risks of all-cause mortality [32]. A previous study found that metformin could be used for treating cardiovascular diseases in hypertension [33], while another study reported that metformin did not reduce blood pressure in hypertensive patients without diabetes [34]. Metformin could improve prognosis in prediabetic patients with acute myocardial infarction by reducing inflammatory tone [35]. Based on previous studies and our research conclusions, we speculated that for atherosclerosis-related diseases (such as cerebral infarction, myocardial infarction) with diabetes, MET treatment before the disease onset might improve the prognosis and in patients with cerebral hemorrhage caused by hypertension,

Table 2: The discharge and follow-up information of those included ICH patients stratified according to MET use.a.

|                  | ALL       | MET (+)   | MET (-)   |
|------------------|-----------|-----------|-----------|
| Discharge, N     | 730       | 281       | 449       |
| Died             | 58 (7.9 [6.0-9.9]) | 18 (6.4 [3.5-9.3]) | 40 (8.9 [6.3-11.5]) |
| Survivors        | 672 (92.1 [90.1-94.0]) | 263 (93.6 [90.7-96.5]) | 409 (91.1 [88.5-93.7]) |
| mRS of survivors | 2 (1-4)   | 2 (1-4)   | 2 (1-4)   |
| Discharge against medical advice | 83 (11.4 [9.1-13.7]) | 30 (10.7 [7.1-14.3]) | 53 (11.8 [8.8-14.8]) |
| Follow-up at 1 year after admission | 672       | 263       | 409       |
| Lost follow-up   | 73 (10.9) | 22 (8.4)  | 51 (12.5) |
| Finished follow-up | 599 (90.1) | 241 (91.6) | 358 (87.5) |
| Died             | 108 (18.0 [15.0-21.1]) | 37 (14.1 [9.9-18.3]) | 71 (17.4 [13.7-21.0]) |
| Survivors        | 491 (82.0) | 204 (85.9) | 287 (82.6) |
| mRS 0            | 139 (28.3) | 57 (27.9)  | 82 (28.6)  |
| mRS 1            | 99 (20.2)  | 42 (20.6)  | 57 (19.9)  |
| mRS 2            | 97 (19.8)  | 47 (23.0)  | 50 (17.4)  |
| mRS 3            | 70 (14.3)  | 23 (11.3)  | 47 (16.4)  |
| mRS 4            | 58 (11.8)  | 23 (11.3)  | 35 (12.2)  |
| mRS 5            | 28 (5.7)   | 12 (5.9)   | 16 (5.6)   |
| Disability ratea | 156 (31.8 [27.7-35.9]) | 58 (28.4 [22.2-34.6]) | 98 (34.1 [28.7-39.6]) |
| Recurrence rate among survivors | 30 (6.1 [4.0-8.2]) | 13 (6.4 [3.0-9.7]) | 17 (5.9 [3.2-8.7]) |

Abbreviation: mRS: Modified Rankin Scale; CI: confidence interval; MET: metformin. aDisability event was defined as an mRS of 3 to 5 points.
the effect was not clear. The relationship between metformin uses, and the prognosis of hemorrhagic stroke needs further clinical research.

Previous studies showed that hematoma volume was perhaps the most important variable when determining outcomes [36–38]. In this study, we also found that hematoma volume was an outcome predictor for mortality and disability events. Furthermore, we found that MET (+) patients had a lower median baseline hematoma volume than did MET (-) patients. However, pre-ICH metformin use was not associated with 1-year prognosis in diabetic ICH patients. Thus, the relationship between metformin use, hematoma volumes, and patient prognosis could not be confirmed.

Whether metformin use affects diabetic ICH patient prognosis by changing hematoma volume needs further research to verify.

Oxidative stress caused by components of the lysed erythrocytes contributes to brain injury after ICH [39], and superoxide contributes to spontaneous ICH’s pathogenesis through activation of matrix metalloproteinase-9 [40]. Metformin could activate oxidative stress and the antioxidant system. Metformin promotes benefits to oxidative stress control in the muscle of hypoinsulinemic rats [41]. Metformin improves obese male fertility by alleviating oxidative stress-induced blood-testis barrier (BTB) damage [42]. Metformin inhibits oxidative stress-mediated cholesterol uptake via SREBP2 [43]. In ligation-induced periodontitis in rats, metformin use could decrease the inflammatory response, oxidative stress, and bone loss [44]. Metformin could delay vascular dysfunction in Goto-Kakizaki rats by reducing mitochondrial oxidative stress [45]. We speculated that metformin might play a role in ICH’s prognosis by regulating the oxidative stress response. However, our research results did not support this conclusion, and more clinical studies need to verify the hypothesis.

Recent studies had found that metformin played roles in heart and pancreatic β cells [46]. The anti-inflammatory and antioxidative properties of metformin might also indirectly improve endothelial function in the cardiovascular system [47]. Bonnefont-Rousselot et al. [2] showed that metformin could directly scavenge reactive oxygen species (ROS), of which NADPH oxidase constitutes the major source. Metformin attenuated the development of atherosclerosis by reducing Drp1-mediated mitochondrial fission in an AMPK-dependent manner [48].

The neuroprotective effect of metformin had been proposed. One study suggested that metformin administration could improve neurobehavioral function following traumatic brain injury by inhibiting microglia activation-mediated inflammation via NF-κB and MAPK signaling pathways [49]. Another study showed that metformin could exert a neuroprotective effect by activating the PI3K/Akt signaling pathway [50]. Also, in acute stroke patients with type 2 diabetes, metformin could improve the neurological function and oxidative stress status by the AMPK/mTOR signaling pathway and oxidative stress [51], and in acute ischemic injury, prestroke metformin treatment was neuroprotective involving AMPK reduction [52]. Metformin was a favorable target in therapeutic intervention of cerebral ischemia injury models [53].

This study has many research limitations. First, this study is a single-center and only includes Chinese. Research representativeness needs to be explained carefully. Second, observational research cannot draw causal conclusions [54]. Whether metformin use could improve diabetic ICH patients’ prognosis needs further verification by randomized, double-blind controlled trials. Third, this study spans a long time, nearly ten years; during the study period, ICH patients’ management plan has undergone significant changes. Lastly, newly diagnosed diabetic patients during follow-up may also use metformin, which has a confounding effect on our research. Also, detailed glucose profiles beyond admission and medical complications following admission are not collected, which could have provided insight into the potential role of metformin in ICH prognosis.

5. Conclusions

Pre-ICH metformin use was not associated with inhospital mortality and 1-year prognosis in diabetic ICH patients. Improving the prognosis of diabetic ICH patients by taking metformin requires further verification.
Data Availability

Please contact the corresponding author for data requests.

Additional Points

Research in context. What is already known about this subject? Metformin is the first-line drug for the treatment of type 2 diabetes mellitus. Metformin use could reduce the risk of hypertension and stroke. Metformin treatment had a better functional outcome in patients with diabetes and ischemic stroke. What is the key question? The associations between metformin treatment and prognosis in intracerebral hemorrhage (ICH) patients with diabetes have not been discussed. What are the new findings? The inhospital mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group (6.4% vs 8.9%, respectively; absolute difference, −2.5% [95% CI, −3.9% to −0.7%]; OR, 0.70 [95% CI, 0.39 to 1.27]; P = 0.22). The 1-year mortality events were not significantly reduced in the MET (+) group compared with the MET (-) group. The 1-year disability and recurrence events were not significantly reduced in the MET (+) group compared with the MET (-) group. How might this impact on clinical practice in the foreseeable future? Pre-ICH metformin use was not associated with inhospital mortality and 1-year prognosis in diabetic ICH patients.

Ethical Approval

The Human Research Ethics Committee of the Shandong University Qilu Hospital checked and approved the study protocol. All enrolled patients need to sign an informed consent form before enrolment.

Disclosure

The sponsor had no role in the study's design and conduct; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

ZX and LQ had full access to all of the data in the study and took responsibility for the integrity of the data and the data analysis accuracy. Study concept and design were contributed by TW, ZQ, WK, WY, ZX, and LQ. Acquisition, analysis, or interpretation of data were contributed by all the authors. Statistical analysis was contributed by TW, ZQ, and WK. Administrative, technical, or material support was contributed by TW, ZQ, and WY. Drafting of the manuscript was contributed by TW, ZQ, and WK. Critical revision of the manuscript for important intellectual content were contributed by all the authors. Study supervision was contributed by SB and LQ. Obtained funding was contributed by TW, ZQ, and SB. Wen-Jun Tu and Qingjia Zeng contributed equally to this work as co-first authors.

Acknowledgments

We thank all team members and patients who participated in the study. This study was supported by grants from the Taishan Scholar Project of Shandong Province (ts201712102), Technology Ministry of Science and Technology Support Program (2015BAI06B05), Natural Science Foundation of Tianjin (No. 19JCJC26600), China Postdoctoral Science Foundation (Nos. 2019M660921 and 2020T130436), and Science Foundation for Post Doctorate Research of the Beijing (Nos. 2017-ZZ-123 and 2020-ZZ-005).

References

[1] M. Foretz, B. Guigas, and B. Viollet, "Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus," Nature Reviews Endocrinology, vol. 15, no. 10, pp. 569–589, 2019.
[2] D. Bonnefont-Rousselot, B. Raji, S. Walrand et al., "An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress," Metabolism, vol. 52, no. 5, pp. 586–589, 2003.
[3] A. A. Alhaider, H. M. Korashy, M. M. Sayed-Ahmed, M. Mobark, H. Kifouri, and M. A. Mansour, "Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression," Chemico-Biological Interactions, vol. 192, no. 3, pp. 233–241, 2011.
[4] A. Chakraborty, S. Chowdhury, and M. Bhattacharyya, "Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients," Diabetes Research and Clinical Practice, vol. 93, no. 1, pp. 56–62, 2011.
[5] A. Esteghamati, D. Eskandari, H. Mirmiranpour et al., "Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial," Clinical Nutrition, vol. 32, no. 2, pp. 179–185, 2013.
[6] J. Škrha, M. Prázný, J. Hilgertová, J. Kvasnička, M. Kalousová, and T. Zima, "Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus," European Journal of Pharmacology, vol. 63, no. 12, pp. 1107–1114, 2007.
[7] H. Yu, X. Zhong, P. Gao et al., "The potential effect of metformin on cancer: an umbrella review," Frontiers in Endocrinology, vol. 10, 2019.
[8] A. S. Kulkarni, S. Gubbi, and N. Barzilai, "Benefits of metformin in attenuating the hallmarks of aging," Cell Metabolism, vol. 32, no. 1, pp. 15–30, 2020.
[9] W. Torres, M. Nava, N. Galbán et al., "Anti-aging effect of metformin: a molecular and Therapeutical perspective," Current Pharmaceutical Design, vol. 26, no. 35, pp. 4496–4508, 2020.
[10] J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, and M. P. Moore, "Metformin versus insulin for the treatment of gestational diabetes," New England Journal of Medicine, vol. 358, no. 19, pp. 2003–2015, 2008.
[11] A. Dean, M. Nielsen, L. Loughlin, I. P. Salt, and M. R. MacLean, "Metformin reverses development of pulmonary hypertension.
via aromatase inhibition,” *Hypertension*, vol. 68, no. 2, pp. 446–454, 2016.

[12] E. A. Day, R. J. Ford, B. K. Smith et al., “Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss,” *Nature Metabolism*, vol. 1, no. 12, pp. 1202–1208, 2019.

[13] C. H. Tseng, “Metformin and risk of hypertension in Taiwanese patients with type 2 diabetes mellitus,” *Journal of the American Heart Association*, vol. 7, no. 13, 2018.

[14] Y. Y. Cheng, H. B. Leu, T. J. Chen et al., “Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study,” *Journal of Stroke and Cerebrovascular Diseases*, vol. 23, no. 2, pp. e99–e105, 2014.

[15] I. Arbelaez-Quintero and M. Palacios, “To use or not to use metformin in cerebral ischemia: a review of the application of metformin in stroke rodents,” *Stroke research and treatment*, vol. 2017, 13 pages, 2017.

[16] Y. Mima, T. Kuwashiro, M. Yasaka et al., “Oxidative brain injury from extravasated erythrocytes after intracerebral hemorrhage,” *Journal of Neuropathology and Experimental Neurology*, vol. 58, no. 1, 1980.

[17] T. Leech, N. Chattipakorn, and S. C. Chattipakorn, “Impact of metformin adherence and all-cause mortality among new users of metformin: a nested case-control study,” *Annals of Pharmacotherapy*, vol. 52, no. 4, pp. 305–313, 2018.

[18] C. Chen, A. Kassan, D. Castañeda, M. Gabani, S. K. Choi, and M. Kassan, “Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway,” *Hypertension Research*, vol. 42, no. 7, pp. 960–969, 2019.

[19] V. C. Júnior, F. D. Fuchs, B. D. Schaan, L. B. Moreira, S. C. Fuchs, and M. Gus, “Effects of metformin on blood pressure in patients with hypertension: a randomized clinical trial,” *Endocrine*, vol. 63, no. 2, pp. 252–258, 2019.

[20] C. Sardu, N. D’Onofrio, M. Torella et al., “Periconceptional vitamin D, folate, and major adverse cardiac events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 126, 2019.

[21] M. A. LoPresti, S. S. Bruce, E. Camacho et al., “Hematoma volume as the major determinant of outcomes after intracerebral hemorrhage,” *Journal of the Neurological Sciences*, vol. 345, no. 1–2, pp. 3–7, 2014.

[22] S. M. Davis, J. Broderick, M. Hennerici et al., “Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage,” *Neurology*, vol. 66, no. 8, pp. 1175–1181, 2006.

[23] H. Huang, G. Huang, J. Gu, K. Chen, Y. Huang, and H. Xu, “Relationship of serum uric acid to hematoma volume and prognosis in patients with acute supratentorial intracerebral hemorrhage,” *World Neurosurgery*, vol. 143, pp. e604–e612, 2020.

[24] J. Wu, Y. Hua, R. F. Keep, T. Schallert, J. T. Hoff, and G. Xi, “Oxidative brain injury from extravasated erythrocytes after intracerebral hemorrhage,” *Brain Research*, vol. 953, no. 1–2, pp. 45–52, 2002.

[25] Y. Wakisaka, Y. Chu, J. D. Miller, G. A. Rosenberg, and D. D. Heistad, “Critical role for copper/zinc-superoxide dismutase in preventing spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice,” *Stroke*, vol. 41, no. 4, pp. 790–797, 2010.

[26] D. Vilela, L. G. Peixoto, R. T. Teixeira et al., “The role of metformin in controlling oxidative stress in muscle of diabetic...
rats,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, 9 pages, 2016.

[42] J. Ye, D. Luo, X. Xu et al., “Metformin Improves Fertility in Obese Males by Alleviating Oxidative Stress-Induced Blood-Testis Barrier Damage,” *Oxidative medicine and cellular longevity*, vol. 2019, 17 pages, 2019.

[43] R. Gopoju, S. Panangipalli, and S. Kotamraju, “Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis,” *Free Radical Biology and Medicine*, vol. 118, pp. 85–97, 2018.

[44] A. A. de Araújo, A. D. S. B. F. Pereira, C. A. C. X. de Medeiros et al., “Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis,” *Plo S one*, vol. 12, no. 8, p. e0183506, 2017.

[45] P. Rösen and N. F. Wiernsperger, “Metformin delays the manifestation of diabetes and vascular dysfunction in Goto–Kakizaki rats by reduction of mitochondrial oxidative stress,” *Diabetes/Metabolism Research and Reviews*, vol. 22, no. 4, pp. 323–330, 2006.

[46] X. Yang, Z. Xu, C. Zhang, Z. Cai, and J. Zhang, “Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells,” *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, vol. 1863, no. 8, pp. 1984–1990, 2017.

[47] L. Nesti and A. Natali, “Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 27, no. 8, pp. 657–669, 2017.

[48] Q. Wang, M. Zhang, G. Torres et al., “Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission,” *Diabetes*, vol. 66, no. 1, pp. 193–205, 2017.

[49] L. Tao, H. L. Di Li, F. Jiang et al., “Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-κB and MAPK signaling pathway,” *Brain Research Bulletin*, vol. 140, pp. 154–161, 2018.

[50] G. Tang, H. Yang, J. Chen et al., “Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway,” *Oncotarget*, vol. 8, no. 58, 2017.

[51] M. Zhao, X. W. Li, D. Z. Chen et al., “Neuro-protective role of metformin in patients with acute stroke and type 2 diabetes mellitus via AMPK/mammalian target of rapamycin (mTOR) signaling pathway and oxidative stress,” *Medical science monitor: international medical journal of experimental and clinical research*, vol. 25, 2019.

[52] T. Deng, Y.-R. Zheng, W.-W. Hou et al., “Pre-stroke metformin treatment is neuroprotective involving AMPK reduction,” *Neurochemical Research*, vol. 41, no. 10, pp. 2719–2727, 2016.

[53] R. Yuan, Y. Wang, Q. Li et al., “Metformin reduces neuronal damage and promotes neuroblast proliferation and differentiation in a cerebral ischemia/reperfusion rat model,” *Neuroreport*, vol. 30, no. 3, pp. 232–240, 2019.

[54] L. S. Cheng, W. J. Tu, Y. Shen, L. J. Zhang, and K. Ji, “Combination of high-sensitivity C-reactive protein and homocysteine predicts the post-stroke depression in patients with ischemic stroke,” *Molecular Neurobiology*, vol. 55, no. 4, pp. 2952–2958, 2018.